Cytokinetics Inc

CYTK

Equity

ISIN null / Valor 21533074

NASDAQ (2025-11-14)

USD 66.44+1.40%

Cytokinetics Inc
UMushroom community rating:

4.33 3 votes No rating yet

NegativeNeutralPositive

About company

Cytokinetics Inc. is a biopharmaceutical company with a specialized focus on the development of innovative therapies aimed at enhancing muscle function for individuals suffering from debilitating diseases where muscle performance is compromised. Established over 25 years ago in South San Francisco, California, the company has carved a niche in muscle biology, pioneering the discovery, development, and commercialization of muscle activators and inhibitors. These novel therapeutic agents are designed as potential treatments for a range of serious conditions affecting muscle health. Under the leadership of experienced industry professionals, Cytokinetics has made significant strides in scientific research, evidenced by its extensive portfolio of over 115 scientific publications, participation in more than 100 clinical trials, and the securing of numerous patents. The company's commitment to advancing muscle biology research extends to its active engagement with the healthcare and scientific communities through peer-reviewed journals and medical forums, aiming to contribute meaningfully to patient care and medical knowledge.

Summarized from source with an LLMView SourceSector: Technology

Revenue Growth

Total revenues for the second quarter of 2025 were $66.8 million, a substantial increase from $0.2 million in the second quarter of 2024. This growth was primarily driven by a $52.4 million recognition related to the license and collaboration agreement for aficamten in Japan with Bayer, and $11.7 million from achieving clinical milestones in Japanese HCM trials.

Research and Development Expenses

R&D expenses for the second quarter of 2025 were $112.6 million, up from $79.6 million in the same period in 2024. The increase was mainly due to advancing clinical trials, higher personnel-related costs, and expanded medical affairs activities.

General and Administrative Expenses

General and Administrative expenses rose to $65.7 million in the second quarter of 2025 from $50.8 million in the second quarter of 2024. The rise was attributed to increased investments in commercial readiness and higher personnel-related costs.

Net Loss

Net loss for the second quarter of 2025 was $134.4 million, or $(1.12) per share, compared to a net loss of $143.3 million, or $(1.31) per share, for the same period in 2024.

Financial Position

As of June 30, 2025, Cytokinetics Inc had approximately $1.0 billion in cash, cash equivalents, and investments, a decrease of $52.6 million from $1.1 billion as of March 31, 2025. The company also received $75 million from the Royalty Pharma Multi Tranche Term Loan in the second quarter of 2025.

Financial Guidance

The company is maintaining its full-year 2025 financial guidance, expecting GAAP operating expenses between $670 million and $710 million. This includes investments toward commercial readiness for the potential approval and launch of aficamten for patients with obstructive HCM.

Summarized from source with an LLMView Source

Key figures

21.5%1Y

66.6%3Y

302%5Y

Performance

61.8%1Y

66.0%3Y

65.4%5Y

Volatility